Vaccine Development Services for Diabetes
Vaccines provide a long-term approach to managing diabetes and are an important component of diabetes intervention. Ace Therapeutics provides comprehensive solutions for diabetes vaccine development, encompassing the full processes from target identification to preclinical evaluation. Leveraging our cutting-edge drug discovery, vaccine development, and preclinical testing platforms, we are dedicated to assisting our clients in turning innovative diabetes vaccine concepts into viable candidates, ultimately advancing more effective diabetes management strategies.
Introduction of Diabetes Vaccine
Currently, a variety of vaccines are being studied for the prevention of diabetes.
|
Protein-based approach in vaccine production |
- IL-1β-targeted epitope peptide (1βEPP) as a new vaccine candidate for T2DM
- Dipeptidyl peptidase-4 inhibitor (DPP4) as novel vaccine candidate for T2DM
- CTB-insB vaccination candidate to treat T1DM
|
| Specific self-antigens approach in vaccine production |
- IA-2 as new vaccine candidate for T1DM
- Glutamic acid decarboxylase 65-kD (GAD65): A new vaccine candidate for T1DM
- Insulin as a target in new vaccine candidate for T1DM
|
| Non-antigen specific approach in vaccine production |
- Live pathogen salmonella as vector vaccine
- Inactivated microbial vaccines
- BCG as vector vaccine in clinical trial studies
|
Vaccines serve as a more effective prophylaxis for diabetes, delaying or preventing the onset of this chronic disease. The mechanisms of action of vaccines vary widely, such as elimination of self-reactive T cells and suppression of interactions between immune cells. Currently, most diabetes vaccines in development have been tested in animal models. Ace Therapeutics is committed to providing comprehensive support to help customers develop more effective diabetes vaccines.
Fig. 1 T1DM and vaccine adjuvant's mechanisms of action. (Chellappan, D. K. et al., 2022)
Diabetes Vaccine Development Services Offered by Ace Therapeutics
- Target discovery and validation
With our expertise in diabetes mechanism research, we offer precise screening of immunomodulatory targets for diabetes vaccine development. In addition, we comprehensively evaluate the efficacy and safety of targets through in vivo and in vitro models to provide a scientific basis for vaccine design.
- Vaccine design & optimization
We provide one-stop services for antigen design, adjuvant selection, and vector development to ensure that vaccine candidates can be designed to effectively activate the immune system. In addition, we evaluate vaccine candidates to optimize their immunogenicity and stability through appropriate preclinical models, testing methods, and necessary immunological tools.
- Preclinical assessment services
We conduct comprehensive analyses of the immunogenicity, pharmacokinetics, toxicity and safety, and stability of diabetes vaccine candidates in animal models to ensure safety, efficacy, and quality consistency.
Advantages of Vaccine Development Services for Diabetes
- Customized preclinical solutions for diabetes based on the client's disease of interest and development needs.
- One-stop service from target discovery to preclinical evaluation ensures an efficient vaccine development process.
- Advanced bioinformatics tools, immunology knowledge and preclinical modeling ensure reliability and safety of vaccine development.
At Ace Therapeutics, our experts are dedicated to offering specialized solutions that assist our clients in developing safe and effective diabetes vaccines. Please contact us for further information. Our experts will work with you to develop and advance innovation in the field of diabetes.
Reference
- Chellappan, D. K.; et al. "Vaccine for Diabetes-Where Do We Stand?" International journal of molecular sciences. 23.16 (2022): 9470.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
